Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis

Trial Profile

Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2018

At a glance

  • Drugs ANB 020 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Sponsors AnaptysBio
  • Most Recent Events

    • 17 Feb 2018 Results published in the AnaptysBio media release.
    • 17 Feb 2018 According to an AnaptysBio media release, data from this trial was presented at the American Academy of Dermatology (AAD) Annual Meeting (2018).
    • 07 Feb 2018 Data from this trial will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting, according to an AnaptysBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top